18,382 Shares in Inspire Medical Systems, Inc. $INSP Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,382 shares of the company’s stock, valued at approximately $820,000.

Several other institutional investors have also added to or reduced their stakes in INSP. CWM LLC lifted its stake in Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares during the last quarter. Havemeyer Place LP bought a new position in shares of Inspire Medical Systems in the 4th quarter valued at $39,000. Smartleaf Asset Management LLC increased its stake in shares of Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after purchasing an additional 205 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 130 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on INSP. Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a research report on Tuesday, August 4th. Evercore set a $54.00 target price on Inspire Medical Systems in a research report on Tuesday, August 4th. Mizuho boosted their target price on Inspire Medical Systems from $55.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Truist Financial reissued a “hold” rating and set a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and an average price target of $66.19.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $57.43 on Wednesday. The firm’s fifty day moving average price is $49.98 and its two-hundred day moving average price is $52.92. The stock has a market cap of $1.66 billion, a PE ratio of 12.43, a PEG ratio of 4.34 and a beta of 0.70. Inspire Medical Systems, Inc. has a fifty-two week low of $38.91 and a fifty-two week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. During the same period in the prior year, the company earned $0.45 EPS. Inspire Medical Systems’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, sell-side analysts predict that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is currently owned by insiders.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.